Vanda Pharmaceuticals (VNDA) Accumulated Expenses (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Accumulated Expenses data on file, last reported at $75.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 27.83% year-over-year to $75.0 million; the trailing twelve-month figure through Mar 2026 stood at $75.0 million (up 27.83% YoY), and the FY2025 full-year result was $76.9 million, up 26.23% from the prior year.
• Accumulated Expenses eased to $75.0 million in Q1 2026, from $76.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $76.9 million in Q4 2025 to a low of $38.2 million in Q2 2022.
• A 5-year average of $55.7 million and a median of $55.5 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 49.19% in 2023 and decreased 5.34% in 2024, its largest moves.
• Tracing VNDA's Accumulated Expenses over 5 years: stood at $45.9 million in 2022, then grew by 7.31% to $49.2 million in 2023, then climbed by 23.68% to $60.9 million in 2024, then increased by 26.23% to $76.9 million in 2025, then fell by 2.48% to $75.0 million in 2026.
• Business Quant data shows VNDA's Accumulated Expenses at $75.0 million in Q1 2026, $76.9 million in Q4 2025, and $70.3 million in Q3 2025.